Last reviewed · How we verify

Placebo (human albumin 1%) — Competitive Intelligence Brief

Placebo (human albumin 1%) (Placebo (human albumin 1%)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Plasma volume expander / Colloid. Area: Critical Care / Hematology.

phase 3 Plasma volume expander / Colloid Critical Care / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo (human albumin 1%) (Placebo (human albumin 1%)) — Biotest. Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo (human albumin 1%) TARGET Placebo (human albumin 1%) Biotest phase 3 Plasma volume expander / Colloid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Plasma volume expander / Colloid class)

  1. Biotest · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo (human albumin 1%) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-human-albumin-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: